Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Serotype 9 AAV Therapy
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Elpida
Deal Size : Undisclosed
Deal Type : Partnership
Viralgen & Elpida Partner for SPG50 & CMT4J Trials
Details : Viralgen Vector Core and Elpida Therapeutics partner to manufacture adeno-associated vector serotype 9 (AAV9) based therapies, including MELPIDA, for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trial...
Brand Name : MELPIDA
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 28, 2023
Lead Product(s) : Serotype 9 AAV Therapy
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Elpida
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : AXO-AAV-GM1
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Sio Gene Therapies
Deal Size : Undisclosed
Deal Type : Partnership
Axovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing Partnership
Details : Axovant will have access to manufacturing resources for Axovant’s AAV-based gene therapy programs, AXO-AAV-GM1 for GM1 gangliosidosis and AXO-AAV-GM2 for GM2 gangliosidosis with sufficient capacity to support ongoing development and eventual commercial...
Brand Name : AXO-AAV-GM1
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 15, 2020
Lead Product(s) : AXO-AAV-GM1
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Sio Gene Therapies
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?